FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug

FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug

Source: 
Endpoints
snippet: 

The FDA in-house review highlights a disagreement of investigators’ use of a key endpoint by Horizon Pharma in the late-stage trial for the top drug in its pipeline, but largely agreed that the antibody was effective.